DexCom, Inc. (DXCM) has recently been in news due to various factors. Several law firms have announced class action lawsuits against the bio-tech company, accusing it of misleading investors by disguising evidence of poor execution brought about by changes in its sales force. The stock is currently ‘down roughly 41%’ as reported by Jim Cramer. Additionally, the company has faced intense scrutiny due to a disappointing growth rate. However, despite these challenges, some investors and analysts still advocate for the potential of the stock, qualifying it as a 'strong buy'. This, in part, may be due to the company's unique continuous glucose monitoring system (CGM), G7 which has even been used in space as part of the first-of-its-kind Polaris Dawn Mission. DexCom has also scheduled its third-quarter 2024 earnings release and conference call for October 24, 2024 at 4:30 p.m. Eastern Time. Despite the stock's current downtrend, it is advised to retain the DexCom stock due to its perceived long-term potential.
Dexcom DXCM News Analytics from Fri, 26 Jul 2024 07:00:00 GMT to Sat, 12 Oct 2024 15:17:10 GMT -
Rating -5
- Innovation 6
- Information 5
- Rumor -7
